# Peginterferon α-2b as a Maintenance Therapy in Participants With Multiple Myeloma Who Responded to Induction Therapy (P01972-AM7)

> **NCT00732641** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 244 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Peginterferon

## Key facts

- **NCT ID:** NCT00732641
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-12
- **Primary completion:** 2010-11
- **Final completion:** 2010-11
- **Target enrollment:** 244 (ACTUAL)
- **Last updated:** 2017-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00732641

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00732641, "Peginterferon α-2b as a Maintenance Therapy in Participants With Multiple Myeloma Who Responded to Induction Therapy (P01972-AM7)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00732641. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*